It was founded in 1868 as the Newark German Hospital, and was renamed in 1952 in honor of Clara Maass, a former nurse who trained there at the hospital's Christina Trefz Training School for Nurses, and become the hospital's head nurse. Maass' 1901 death during yellow fever experiments attracted national attention.In 1956 a new building was completed in Belleville, which is sometimes referred to as "The Hospital in the Park" due to its location opposite Branch Brook Park. In 2009, the hospital was staffed by over 550 physicians with 1,600 total employees..
Meropenem-vaborbactam (MEV) is a novel β-lactam β-lactamase inhibitor combination approved in the United States for the treatment of complicated urinary tract infections caused by resistant organisms. Its spectrum includes carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. Limited data exist on the use of MEV in patients with reduced renal function. This study compared clinical characteristics and outcomes between patients with moderate to severe renal impairment and those with mild or no impairment.Table 1.Baseline, infection, and treatment characteristics.Table 2.Clinical outcomes. This was a real-world, multicenter, retrospective cohort study conducted between 2017 and 2025 in adult patients who received MEV for ≥72 hours. Patients with KDOQI CKD stages 3-5 or GFR < 60 mL/min/1.73m2 or on chronic dialysis were assigned to the renal impairment (RI) group. All other patients were assigned to the non-impaired (NI) group. The primary outcome was clinical success, defined as resolution or improvement in signs of infection without recurrence. Secondary outcomes included 30-day all-cause mortality, 30-day microbiologic recurrence, 30-day hospital readmission, and occurrence of treatment-emergent adverse events. Seventy-two patients were included in the RI group and 151 patients were included in the NI group. The median baseline eGFR was 52.3 vs. 91.3 mL/min/1.73m2 in the RI and NI groups, respectively. Nearly half (47%) of patients in the RI group were receiving chronic dialysis. Clinical success was achieved in 76% of patients in the RI group compared to 79% in the NI group (p=0.60). Thirty-day all-cause mortality was 20.8% in the RI group vs. 23.8% the in the NI group (p=0.62). Thirty-day microbiological recurrence and hospital readmission rates were similar between the two groups. Adverse events were rare in both groups and similar in incidence (2.8% vs. 2.6% in the RI and NI groups, respectively [p=0.96]). This study demonstrated the clinical outcomes of MEV when used in patients with moderate to severe renal impairment. Prospective randomized trials in this patient population are needed to validate these findings. Kevin W. Garey, PharmD, MS, FIDSA, FASHP, Acurx: Grant/Research Support|Merck & Co.: Grant/Research Support|Paratek Pharmaceuticals: Grant/Research Support Wesley D. Kufel, Pharm.D., BCPS, BCIDP, Merck & Co.: Grant/Research Support|Shionogi, Inc: Grant/Research Support|Shionogi, Inc: Honoraria Tamara Krekel, PharmD, BCPS, BCIDP, AbbVie: Advisor/Consultant|AbbVie: Honoraria|Shionogi: Advisor/Consultant|Shionogi: Honoraria Taylor Morrisette, PharmD, MPH, AbbVie Inc: Advisor/Consultant|AbbVie Inc.: Grant/Research Support|Copeland, Stair Valz & Lovell: Expert Testimony|Infectious Diseases Special Edition: Honoraria|Stellus Rx: Grant/Research Support Travis J. Carlson, PharmD, BCIDP, Aimmune Therapeutics, Inc.: Speaker bureau Venugopalan Veena, PharmD, Merck: Grant/Research Support Vasilios Athans, PharmD, BCIDP, Astellas Pharma: Advisor/Consultant Kimberly C. Claeys, PharmD, PhD, bioMérieux: Advisor/Consultant|bioMérieux: Honoraria Michael J. Rybak, PharmD, PhD, MPH, Abbvie: Grant/Research Support|Innoviva: Grant/Research Support|Melina: Grant/Research Support|Merck: Grant/Research Support|Shionogi: Grant/Research Support
Omadacycline (OMC) is an aminomethylcycline antibiotic approved in 2018 for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. This study assessed the effectiveness and safety of OMC in real-world clinical settings across the United States. We conducted a multicenter, retrospective cohort study at 12 U.S. medical centers including adults who received OMC between October 2018 and October 2023. The primary outcome for definitive therapy was clinical cure, defined as resolution of infectious signs and symptoms without the need for alternative therapy due to concern for failure. For suppressive therapy, the primary outcome was breakthrough infection within 90 days, defined as recurrence with the same pathogen at the same site. Secondary outcomes included 30-day survival, recurrence, readmission, and adverse effects (AEs). Eighty-six patients were included; median (interquartile range [IQR]) age was 63 years (46.0–66.0), 52.3
Inpatient antibiotic stewardship programs (ASP) are associated with improved infection cure rates, as well as reduced risk of adverse drug events and antibiotic resistance development. However, there is often limited ASP presence at the discharge setting. Data has shown over 70% of parenteral antibiotic prescriptions at hospital discharge are excessively broad spectrum or have prolonged durations. Additionally, these patients’ discharge planning process is complex, prolonging length of stay (LOS). The objective of this gap analysis is to evaluate the inpatient LOS and antibiotic appropriateness of parenteral antibiotic therapy prescribed at discharge from an urban, non-teaching, community medical center. This IRB-approved retrospective cohort study evaluated adult patients discharged on parenteral antibiotics between January and March 2024. The primary outcome is LOS in days from hospital admission to discharge. We also evaluated antibiotic appropriateness, antibiotic days of therapy, vascular access devices, 30-day readmission rates, and discharge disposition. Antibiotic appropriateness was assessed using the validated National Antibiotic Prescribing Survey (NAPS) which stratifies regimens as appropriate (optimal or adequate), inappropriate (suboptimal or inadequate), or not assessable based on local treatment guidelines, literature references, and patient-specific factors. Inappropriate antibiotic regimens were further evaluated to identify specific opportunities for ASP intervention. Data were evaluated using descriptive statistics, including measures of central tendency and dispersion. A total of 168 patients met inclusion criteria. The average LOS was 10.7±7.7 days. The proportion of appropriate and inappropriate antibiotic regimens were 52.8% and 38.8%, respectively. The most frequently identified opportunities for intervention included improving antibiotic selection, duration, and transition to oral antibiotics. This gap analysis illustrates discharge parenteral antibiotic stewardship metrics, including associated inpatient LOS and antibiotic appropriateness. Based on these findings, we aim to integrate ASPs in discharge planning to close these gaps and improve antibiotic utilization. All Authors: No reported disclosures
Abstract Background: Inpatient antimicrobial stewardship (AMS) programs combat inappropriate antibiotic use, increased resistance, and adverse outcomes. However, stewardship monitoring is limited at transitions of care (TOC), especially for patients being discharged on parenteral antimicrobials. Additionally, discharge planning processes for these patients are often complex, prolonging length of stay (LOS). This highlights an opportunity to optimize outpatient parenteral antimicrobial therapy (OPAT) regimens following inpatient admissions. Objective: To compare LOS in patients discharged with OPAT before versus after a stewardship initiative targeting TOC parenteral antimicrobial therapy (TOC-PAT). Design: Prepost cohort study. Setting: Urban, non-teaching, community medical center. Patients: Adult patients discharged or planned to be discharged on OPAT. Methods: The AMS team developed a novel program monitoring patients being discharged on OPAT. Pharmacists were deployed to identify AMS intervention opportunities. This study evaluated outcomes before and after program implementation. The primary outcome compared inpatient LOS. The secondary outcome assessed antimicrobial appropriateness using the National Antimicrobial Prescribing Survey. Results: The pre- and postimplementation cohorts included 167 and 100 patients, respectively. There was no statistically significant difference in median LOS (9 [6, 13] vs 10 [6,15] days; P = .27). The proportion of appropriate regimens increased from 51.5% to 58%. A total of 68 pharmacist-led AMS interventions were made, 66% of which were accepted by treating teams, primarily modifications in antimicrobial choice and IV to PO conversions. Conclusion: This study serves as a foundation for future OPAT and TOC-PAT stewardship programs. The results of this study highlight pharmacist impact in assessing OPAT regimens to increase antimicrobial appropriateness.
Acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections (DFI), and osteomyelitis often require extended antimicrobial therapy courses. Dalbavancin’s long half-life allows outpatient or emergency department (ED) management of patients not amenable to oral antimicrobials and/or outpatient infusion. To provide a budget-impact analysis and real-world assessment of dalbavancin cost and reimbursement data, and model drug acquisition cost-avoidance compared to daptomycin and oral linezolid in outpatient and ED patients at our institution (New Jersey, USA). All patients treated with dalbavancin in the ED or outpatient wound clinic during the one-year study period with available drug-specific reimbursement data were included. Wholesale acquisition costs were compared between dalbavancin, daptomycin, and oral linezolid. We conducted a regression analysis studying profit changes with patient weight, indication, drug-specific reimbursement, and treatment duration. We fitted a linear mixed-effects model and paired t-test to explore relationships between potential profit and various predictors while accounting for random effects of different indications. Paired t-tests were conducted evaluating potential profit and cost avoidance from the hospital and institutional pharmacy perspective associated with dalbavancin across treatment durations and indications. Eighty-eight individual patient encounters were included in the final analysis. Treatment indications included ABSSSI (48.9
